Date Posted: July 16, 2026

This Local Coverage Determination (LCD) has completed the Open Public and Contractor Advisory Committee (CAC) comment period and is now finalized under contractor numbers: 01111 (CA), 01211 (AS, GU, HI, NMI), 01311 (NV), and 01911 (CA, HI & Territories). Responses to comments received may be found as a link at the bottom of the final LCD.

Medicare Coverage Database (MCD) Number/Contractor Determination Number: L40060

LCD Title: MolDX: Molecular Testing for Solid Organ Allograft Rejection

Effective Date: August 30, 2026

Summary of LCD:

This Medicare contractor will provide limited coverage for molecular and proteomic diagnostic tests used in the evaluation and management of patients who have undergone solid organ transplantation. These tests can inform decision making along with standard clinical assessments in their evaluation of organ injury for active rejection (AR). These tests may be ordered by qualified physicians or providers operating within their scope of practice considering the diagnosis of AR, helping to rule in or out this condition and when assessing the need for or results of a diagnostic biopsy. They should be considered along with other clinical evaluations and results and may be particularly useful in patients with significant contraindications to invasive procedures.

Visit the Proposed MolDX LCDs webpage to access this LCD.